FDA New indication / efficacy supplement: CAMZYOS (mavacamten) — NDA214998/13, Sep 30, 2026. Applicant at approval: Bristol-Myers Squibb Company.
Want filters by date, company class and metro, plus CSV? Use Signals.
INDUSTRY INTELLIGENCE
Industry intelligence
Source-linked FDA, trial, NIH, and funding observations for verified companies. Newswire, recruiter signals, and private notes are not in this public snapshot.
877FDA recordsLast 2 years. 362 companies.
33,436Trials (company is sponsor)1,673 companies.
14,377NIH grantsAnnual amount. 1,253 companies.
2,932Funding eventsLast 2 years. 1,420 companies.
FDA records
877 records · 362 companiesFDA 510(k) clearance: Invisalign System — K262196, Sep 25, 2026. Applicant at approval: Align Technology, Inc.
FDA 510(k) clearance: Xpert Respiratory Panel — K261336, Sep 25, 2026. Applicant at approval: Cepheid.
FDA New indication / efficacy supplement: OLUMIANT (baricitinib) — NDA207924/9, Sep 25, 2026. Applicant at approval: Eli Lilly and Company.
FDA New drug/biologic (novel): ATEBRIOZ (zilurgisertib) — NDA221198, Sep 25, 2026. Applicant at approval: Incyte Corporation.
FDA 510(k) clearance: TumorSight Risk — K260023, Sep 25, 2026. Applicant at approval: SimBioSys, Inc.
FDA 510(k) clearance: corra® cervical plating system — K262149, Sep 24, 2026. Applicant at approval: Carlsmed, Inc.
FDA New indication / efficacy supplement: LENVIMA (lenvatinib mesylate) — NDA206947/35, Sep 24, 2026. Applicant at approval: Eisai Inc.
FDA 510(k) clearance: Pediatric Nailing Platform Femur — K261345, Sep 24, 2026. Applicant at approval: OrthoPediatrics Corp.
FDA New drug/biologic (novel): LYRFIGTU (lirafugratinib hydrochloride) — NDA220425, Sep 23, 2026. Applicant at approval: Elevar Therapeutics Inc.
FDA 510(k) clearance: SABER-C System — K263049, Sep 23, 2026. Applicant at approval: Elevation Spine.
FDA New drug/biologic (novel): ONSWIK (insulin efsitora alfa-gobe) — BLA761408, Sep 23, 2026. Applicant at approval: Eli Lilly and Company.
Trials (company is sponsor)
33,436 records · 1,673 companiesClinical trial NCT07869654 (lead sponsor): A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults. Phase PHASE1; status NOT_YET_RECRUITI
Clinical trial NCT06897839 (lead sponsor): Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD). Phase PHASE2;PHAS
Clinical trial NCT06343805 (lead sponsor): A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Ess
Clinical trial NCT07247266 (lead sponsor): Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndr
Clinical trial NCT06767683 (lead sponsor): A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia. Phase PHASE2;PHASE3; status RECRUITING; start 2025
Clinical trial NCT07358078 (lead sponsor): DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting. Phase n/a; status R
Clinical trial NCT07862647 (lead sponsor): TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma. Phase PHASE1; status RECRUITING; start Oct 29, 2026; primary compl
Clinical trial NCT06662097 (lead sponsor): A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery. Phase PHASE2; status COMPLETED; start Oct 16, 2024; primary completio
Clinical trial NCT06260514 (lead sponsor): Study of APR-1051 in Patients With Advanced Solid Tumors. Phase PHASE1; status RECRUITING; start Jun 13, 2024; primary completion 2027-06 (
Clinical trial NCT06120075 (lead sponsor): A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies. Phase PHASE1; status COMPLETED; start 20
Clinical trial NCT06347016 (lead sponsor): Study of Plozasiran in Adults With Severe Hypertriglyceridemia. Phase PHASE3; status COMPLETED; start Jul 23, 2024; primary completion 2026
Clinical trial NCT06445322 (lead sponsor): Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH). Phase n/a; status RECRUITING; sta
NIH awards
14,377 records · 1,253 companiesNIH award (government grant; not an investment round) 1R44AR087266-01A1 FY2026: $1,007,121 awarded for that fiscal year; activity R44 (SBIR); PI DRAGANSKI, ANDREW R; recipient as w
NIH award (government grant; not an investment round) 1R41AR087258-01A1 FY2026: $323,090 awarded for that fiscal year; activity R41 (STTR); PI KARATEPE, KUTAY; recipient as written
NIH award (government grant; not an investment round) 1R44NS143633-01A1 FY2026: $847,695 awarded for that fiscal year; activity R44 (SBIR); PI LIM, RYAN GAR-LOK; recipient as writt
NIH award (government grant; not an investment round) 5R43NS143450-02 FY2026: $200,070 awarded for that fiscal year; activity R43 (SBIR); PI DOCKENDORFF, CHRISTOPHER; recipient as
NIH award (government grant; not an investment round) 5R01AI193221-02 FY2026: $642,054 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as writte
NIH award (government grant; not an investment round) 3R24AI143502-07S1 FY2026: $531,874 awarded for that fiscal year; activity R24 (OTHER_NIH); PI LAIRD, GREGORY MICHAEL; recipien
NIH award (government grant; not an investment round) 1R41CA306619-01A1 FY2026: $400,000 awarded for that fiscal year; activity R41 (STTR); PI LAMOUILLE, SAMY; recipient as written
NIH award (government grant; not an investment round) 1R44CA314796-01 FY2026: $977,639 awarded for that fiscal year; activity R44 (SBIR); PI WEINBERG, ANDREW D.; recipient as writt
NIH award (government grant; not an investment round) 5R44EY038138-02 FY2026: $1,009,284 awarded for that fiscal year; activity R44 (SBIR); PI WILLIAMS, TERE M.; recipient as writt
NIH award (government grant; not an investment round) 5R44CA291369-02 FY2026: $718,994 awarded for that fiscal year; activity R44 (SBIR); PI KU, JEREMY; recipient as written: EXAI
NIH award (government grant; not an investment round) 1R44DK148134-01 FY2026: $1,061,227 awarded for that fiscal year; activity R44 (SBIR); PI SASSONE-CORSI, MARTINA; recipient as
NIH award (government grant; not an investment round) 4R42CA302331-02 FY2026: $1,006,593 awarded for that fiscal year; activity R42 (STTR); PI RODRIGUEZ, EDGARDO; recipient as writ
Funding observations
2,932 records · 1,420 companiesGovernment grant (not counted as raised): $1M (total, as published), announced Oct 8, 2026. Source: company release on GlobeNewswire.
Follow-on offering: $5M (total, as published), announced Oct 8, 2026. Source: company's own press page.
Partnership / licensing (not counted as raised): amount not published, announced Oct 8, 2026. Source: company's own press page.
Partnership / licensing (not counted as raised): amount not published, announced Oct 8, 2026. Source: company's own press page.
Partnership / licensing (not counted as raised): amount not published, announced Oct 7, 2026. Source: company's own press page.
Government grant (not counted as raised): $28.3M (up to, as announced), announced Oct 7, 2026. Source: company release on GlobeNewswire.
Partnership / licensing (not counted as raised): amount not published, announced Oct 7, 2026. Source: company's own press page.
Government contract (not counted as raised): $96.1M (total, as published), announced Oct 7, 2026. Source: company's own press page.
Private equity round — Series B: $150M (total, as published), announced Oct 7, 2026. Source: company's own press page.
Debt: $500M (not counted as a raise), announced Oct 7, 2026. Source: company release on GlobeNewswire.
Private placement: $40M (total, as published), announced Oct 6, 2026. Source: SEC filing.
Partnership / licensing (not counted as raised): amount not published, announced Oct 6, 2026. Source: company's own press page.